nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentazocine—Abdominal distress—Methotrexate—lymphatic system cancer	0.0367	0.038	CcSEcCtD
Pentazocine—Induration—Bleomycin—lymphatic system cancer	0.0275	0.0284	CcSEcCtD
Pentazocine—Grand mal convulsion—Carmustine—lymphatic system cancer	0.0225	0.0233	CcSEcCtD
Pentazocine—EBP—Azacitidine—Fludarabine—lymphatic system cancer	0.0174	0.514	CbGdCrCtD
Pentazocine—Nodule—Methotrexate—lymphatic system cancer	0.0169	0.0175	CcSEcCtD
Pentazocine—EBP—Azacitidine—Cytarabine—lymphatic system cancer	0.0164	0.486	CbGdCrCtD
Pentazocine—Hepatic function abnormal—Teniposide—lymphatic system cancer	0.0158	0.0164	CcSEcCtD
Pentazocine—Nystagmus—Vincristine—lymphatic system cancer	0.0143	0.0148	CcSEcCtD
Pentazocine—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0135	0.014	CcSEcCtD
Pentazocine—Ulcer—Bleomycin—lymphatic system cancer	0.013	0.0134	CcSEcCtD
Pentazocine—Visual disturbance—Fludarabine—lymphatic system cancer	0.0128	0.0133	CcSEcCtD
Pentazocine—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0123	0.0127	CcSEcCtD
Pentazocine—Tinnitus—Mechlorethamine—lymphatic system cancer	0.0121	0.0125	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.011	0.0113	CcSEcCtD
Pentazocine—Ulcer—Mitoxantrone—lymphatic system cancer	0.0105	0.0109	CcSEcCtD
Pentazocine—Sweating increased—Fludarabine—lymphatic system cancer	0.0102	0.0106	CcSEcCtD
Pentazocine—Sweating—Teniposide—lymphatic system cancer	0.0102	0.0106	CcSEcCtD
Pentazocine—Vertigo—Mechlorethamine—lymphatic system cancer	0.0102	0.0105	CcSEcCtD
Pentazocine—Disorientation—Bleomycin—lymphatic system cancer	0.00997	0.0103	CcSEcCtD
Pentazocine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00922	0.00955	CcSEcCtD
Pentazocine—Flushing—Teniposide—lymphatic system cancer	0.00888	0.00919	CcSEcCtD
Pentazocine—Anorexia—Mechlorethamine—lymphatic system cancer	0.00879	0.0091	CcSEcCtD
Pentazocine—Chills—Teniposide—lymphatic system cancer	0.00859	0.00889	CcSEcCtD
Pentazocine—Visual impairment—Fludarabine—lymphatic system cancer	0.00811	0.00839	CcSEcCtD
Pentazocine—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00802	0.0083	CcSEcCtD
Pentazocine—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00795	0.00823	CcSEcCtD
Pentazocine—Diplopia—Carmustine—lymphatic system cancer	0.00778	0.00806	CcSEcCtD
Pentazocine—Agitation—Teniposide—lymphatic system cancer	0.00766	0.00793	CcSEcCtD
Pentazocine—Chills—Fludarabine—lymphatic system cancer	0.00755	0.00781	CcSEcCtD
Pentazocine—Face oedema—Carmustine—lymphatic system cancer	0.00751	0.00778	CcSEcCtD
Pentazocine—Hypertension—Teniposide—lymphatic system cancer	0.00719	0.00745	CcSEcCtD
Pentazocine—Urinary retention—Vincristine—lymphatic system cancer	0.00706	0.00731	CcSEcCtD
Pentazocine—Confusional state—Teniposide—lymphatic system cancer	0.00686	0.0071	CcSEcCtD
Pentazocine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0068	0.00703	CcSEcCtD
Pentazocine—Agitation—Fludarabine—lymphatic system cancer	0.00673	0.00697	CcSEcCtD
Pentazocine—Tachycardia—Teniposide—lymphatic system cancer	0.00664	0.00687	CcSEcCtD
Pentazocine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00657	0.0068	CcSEcCtD
Pentazocine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00653	0.00675	CcSEcCtD
Pentazocine—Anorexia—Teniposide—lymphatic system cancer	0.00648	0.00671	CcSEcCtD
Pentazocine—Hypotension—Teniposide—lymphatic system cancer	0.00635	0.00658	CcSEcCtD
Pentazocine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00631	0.00653	CcSEcCtD
Pentazocine—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00609	0.0063	CcSEcCtD
Pentazocine—Dyspnoea—Teniposide—lymphatic system cancer	0.00606	0.00628	CcSEcCtD
Pentazocine—Confusional state—Fludarabine—lymphatic system cancer	0.00603	0.00624	CcSEcCtD
Pentazocine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00598	0.00619	CcSEcCtD
Pentazocine—Decreased appetite—Teniposide—lymphatic system cancer	0.00591	0.00612	CcSEcCtD
Pentazocine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00587	0.00607	CcSEcCtD
Pentazocine—Apnoea—Methotrexate—lymphatic system cancer	0.00586	0.00606	CcSEcCtD
Pentazocine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00581	0.00601	CcSEcCtD
Pentazocine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00578	0.00598	CcSEcCtD
Pentazocine—Flushing—Bleomycin—lymphatic system cancer	0.00572	0.00592	CcSEcCtD
Pentazocine—Anorexia—Fludarabine—lymphatic system cancer	0.0057	0.0059	CcSEcCtD
Pentazocine—Feeling abnormal—Teniposide—lymphatic system cancer	0.0056	0.0058	CcSEcCtD
Pentazocine—Chills—Bleomycin—lymphatic system cancer	0.00553	0.00573	CcSEcCtD
Pentazocine—Sweating—Vincristine—lymphatic system cancer	0.00549	0.00568	CcSEcCtD
Pentazocine—Nausea—Mechlorethamine—lymphatic system cancer	0.00548	0.00567	CcSEcCtD
Pentazocine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00537	0.00555	CcSEcCtD
Pentazocine—Hallucination—Carmustine—lymphatic system cancer	0.00536	0.00554	CcSEcCtD
Pentazocine—Sweating—Mitoxantrone—lymphatic system cancer	0.00535	0.00553	CcSEcCtD
Pentazocine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00533	0.00552	CcSEcCtD
Pentazocine—Ulcer—Methotrexate—lymphatic system cancer	0.00525	0.00543	CcSEcCtD
Pentazocine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.0052	0.00539	CcSEcCtD
Pentazocine—Decreased appetite—Fludarabine—lymphatic system cancer	0.0052	0.00538	CcSEcCtD
Pentazocine—Visual impairment—Carmustine—lymphatic system cancer	0.00519	0.00537	CcSEcCtD
Pentazocine—Hallucination—Vincristine—lymphatic system cancer	0.00511	0.00529	CcSEcCtD
Pentazocine—Constipation—Fludarabine—lymphatic system cancer	0.00511	0.00529	CcSEcCtD
Pentazocine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00501	0.00519	CcSEcCtD
Pentazocine—Flushing—Carmustine—lymphatic system cancer	0.005	0.00517	CcSEcCtD
Pentazocine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00493	0.0051	CcSEcCtD
Pentazocine—Asthenia—Teniposide—lymphatic system cancer	0.00488	0.00505	CcSEcCtD
Pentazocine—Pruritus—Teniposide—lymphatic system cancer	0.00481	0.00498	CcSEcCtD
Pentazocine—Diarrhoea—Teniposide—lymphatic system cancer	0.00465	0.00482	CcSEcCtD
Pentazocine—Chills—Mitoxantrone—lymphatic system cancer	0.00449	0.00465	CcSEcCtD
Pentazocine—Confusional state—Bleomycin—lymphatic system cancer	0.00442	0.00457	CcSEcCtD
Pentazocine—Vision blurred—Carmustine—lymphatic system cancer	0.00442	0.00457	CcSEcCtD
Pentazocine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.0044	0.00456	CcSEcCtD
Pentazocine—Tremor—Carmustine—lymphatic system cancer	0.00439	0.00454	CcSEcCtD
Pentazocine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00438	0.00454	CcSEcCtD
Pentazocine—Vomiting—Teniposide—lymphatic system cancer	0.00432	0.00448	CcSEcCtD
Pentazocine—Agitation—Carmustine—lymphatic system cancer	0.00431	0.00446	CcSEcCtD
Pentazocine—Asthenia—Fludarabine—lymphatic system cancer	0.00429	0.00444	CcSEcCtD
Pentazocine—Dermatitis—Teniposide—lymphatic system cancer	0.00428	0.00443	CcSEcCtD
Pentazocine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00427	0.00442	CcSEcCtD
Pentazocine—Headache—Teniposide—lymphatic system cancer	0.00426	0.00441	CcSEcCtD
Pentazocine—Pruritus—Fludarabine—lymphatic system cancer	0.00423	0.00438	CcSEcCtD
Pentazocine—Anorexia—Bleomycin—lymphatic system cancer	0.00418	0.00432	CcSEcCtD
Pentazocine—Agitation—Vincristine—lymphatic system cancer	0.00411	0.00426	CcSEcCtD
Pentazocine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00411	0.00425	CcSEcCtD
Pentazocine—Hypotension—Bleomycin—lymphatic system cancer	0.00409	0.00424	CcSEcCtD
Pentazocine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00409	0.00423	CcSEcCtD
Pentazocine—Hypertension—Carmustine—lymphatic system cancer	0.00405	0.00419	CcSEcCtD
Pentazocine—Nausea—Teniposide—lymphatic system cancer	0.00404	0.00418	CcSEcCtD
Pentazocine—Vertigo—Vincristine—lymphatic system cancer	0.00402	0.00416	CcSEcCtD
Pentazocine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00393	0.00407	CcSEcCtD
Pentazocine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00391	0.00404	CcSEcCtD
Pentazocine—Hypertension—Vincristine—lymphatic system cancer	0.00386	0.004	CcSEcCtD
Pentazocine—Confusional state—Carmustine—lymphatic system cancer	0.00386	0.00399	CcSEcCtD
Pentazocine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00381	0.00394	CcSEcCtD
Pentazocine—Visual disturbance—Methotrexate—lymphatic system cancer	0.0038	0.00394	CcSEcCtD
Pentazocine—Vomiting—Fludarabine—lymphatic system cancer	0.0038	0.00393	CcSEcCtD
Pentazocine—Dermatitis—Fludarabine—lymphatic system cancer	0.00377	0.0039	CcSEcCtD
Pentazocine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00376	0.00389	CcSEcCtD
Pentazocine—Headache—Fludarabine—lymphatic system cancer	0.00374	0.00388	CcSEcCtD
Pentazocine—Tachycardia—Carmustine—lymphatic system cancer	0.00373	0.00386	CcSEcCtD
Pentazocine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00365	0.00378	CcSEcCtD
Pentazocine—Anorexia—Carmustine—lymphatic system cancer	0.00365	0.00377	CcSEcCtD
Pentazocine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00361	0.00374	CcSEcCtD
Pentazocine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00359	0.00371	CcSEcCtD
Pentazocine—Hypotension—Carmustine—lymphatic system cancer	0.00357	0.0037	CcSEcCtD
Pentazocine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00356	0.00368	CcSEcCtD
Pentazocine—Nausea—Fludarabine—lymphatic system cancer	0.00355	0.00367	CcSEcCtD
Pentazocine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00353	0.00365	CcSEcCtD
Pentazocine—Shock—Mitoxantrone—lymphatic system cancer	0.0035	0.00362	CcSEcCtD
Pentazocine—Anorexia—Vincristine—lymphatic system cancer	0.00348	0.0036	CcSEcCtD
Pentazocine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00347	0.00359	CcSEcCtD
Pentazocine—Insomnia—Carmustine—lymphatic system cancer	0.00346	0.00358	CcSEcCtD
Pentazocine—Irritability—Methotrexate—lymphatic system cancer	0.00344	0.00356	CcSEcCtD
Pentazocine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00344	0.00356	CcSEcCtD
Pentazocine—Paraesthesia—Carmustine—lymphatic system cancer	0.00343	0.00356	CcSEcCtD
Pentazocine—Hypotension—Vincristine—lymphatic system cancer	0.00341	0.00353	CcSEcCtD
Pentazocine—Dyspnoea—Carmustine—lymphatic system cancer	0.00341	0.00353	CcSEcCtD
Pentazocine—Somnolence—Carmustine—lymphatic system cancer	0.0034	0.00352	CcSEcCtD
Pentazocine—Anorexia—Mitoxantrone—lymphatic system cancer	0.00339	0.00351	CcSEcCtD
Pentazocine—Decreased appetite—Carmustine—lymphatic system cancer	0.00333	0.00344	CcSEcCtD
Pentazocine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00332	0.00344	CcSEcCtD
Pentazocine—Insomnia—Vincristine—lymphatic system cancer	0.0033	0.00342	CcSEcCtD
Pentazocine—Paraesthesia—Vincristine—lymphatic system cancer	0.00328	0.00339	CcSEcCtD
Pentazocine—Constipation—Carmustine—lymphatic system cancer	0.00327	0.00339	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00325	0.00336	CcSEcCtD
Pentazocine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00323	0.00334	CcSEcCtD
Pentazocine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00319	0.00331	CcSEcCtD
Pentazocine—Decreased appetite—Vincristine—lymphatic system cancer	0.00317	0.00329	CcSEcCtD
Pentazocine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00317	0.00328	CcSEcCtD
Pentazocine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00316	0.00327	CcSEcCtD
Pentazocine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00315	0.00326	CcSEcCtD
Pentazocine—Asthenia—Bleomycin—lymphatic system cancer	0.00314	0.00325	CcSEcCtD
Pentazocine—Constipation—Vincristine—lymphatic system cancer	0.00312	0.00323	CcSEcCtD
Pentazocine—Pruritus—Bleomycin—lymphatic system cancer	0.0031	0.00321	CcSEcCtD
Pentazocine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00309	0.0032	CcSEcCtD
Pentazocine—Eosinophilia—Methotrexate—lymphatic system cancer	0.00308	0.00319	CcSEcCtD
Pentazocine—Constipation—Mitoxantrone—lymphatic system cancer	0.00304	0.00315	CcSEcCtD
Pentazocine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00299	0.00309	CcSEcCtD
Pentazocine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00293	0.00303	CcSEcCtD
Pentazocine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00282	0.00292	CcSEcCtD
Pentazocine—Vomiting—Bleomycin—lymphatic system cancer	0.00279	0.00288	CcSEcCtD
Pentazocine—Dermatitis—Bleomycin—lymphatic system cancer	0.00276	0.00286	CcSEcCtD
Pentazocine—Asthenia—Carmustine—lymphatic system cancer	0.00274	0.00284	CcSEcCtD
Pentazocine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00269	0.00278	CcSEcCtD
Pentazocine—Sweating—Methotrexate—lymphatic system cancer	0.00266	0.00276	CcSEcCtD
Pentazocine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00262	0.00271	CcSEcCtD
Pentazocine—Asthenia—Vincristine—lymphatic system cancer	0.00262	0.00271	CcSEcCtD
Pentazocine—Diarrhoea—Carmustine—lymphatic system cancer	0.00262	0.00271	CcSEcCtD
Pentazocine—Nausea—Bleomycin—lymphatic system cancer	0.0026	0.00269	CcSEcCtD
Pentazocine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00259	0.00268	CcSEcCtD
Pentazocine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00255	0.00264	CcSEcCtD
Pentazocine—Dizziness—Carmustine—lymphatic system cancer	0.00253	0.00262	CcSEcCtD
Pentazocine—Diarrhoea—Vincristine—lymphatic system cancer	0.0025	0.00259	CcSEcCtD
Pentazocine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00243	0.00252	CcSEcCtD
Pentazocine—Vomiting—Carmustine—lymphatic system cancer	0.00243	0.00252	CcSEcCtD
Pentazocine—Dizziness—Vincristine—lymphatic system cancer	0.00241	0.0025	CcSEcCtD
Pentazocine—Dermatitis—Carmustine—lymphatic system cancer	0.00241	0.00249	CcSEcCtD
Pentazocine—Visual impairment—Methotrexate—lymphatic system cancer	0.0024	0.00249	CcSEcCtD
Pentazocine—Headache—Carmustine—lymphatic system cancer	0.0024	0.00248	CcSEcCtD
Pentazocine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00236	0.00244	CcSEcCtD
Pentazocine—Tinnitus—Methotrexate—lymphatic system cancer	0.00233	0.00241	CcSEcCtD
Pentazocine—Vomiting—Vincristine—lymphatic system cancer	0.00232	0.0024	CcSEcCtD
Pentazocine—Dermatitis—Vincristine—lymphatic system cancer	0.0023	0.00238	CcSEcCtD
Pentazocine—Headache—Vincristine—lymphatic system cancer	0.00229	0.00237	CcSEcCtD
Pentazocine—Nausea—Carmustine—lymphatic system cancer	0.00227	0.00235	CcSEcCtD
Pentazocine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00226	0.00234	CcSEcCtD
Pentazocine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00224	0.00232	CcSEcCtD
Pentazocine—Chills—Methotrexate—lymphatic system cancer	0.00224	0.00232	CcSEcCtD
Pentazocine—Headache—Mitoxantrone—lymphatic system cancer	0.00223	0.00231	CcSEcCtD
Pentazocine—Nausea—Vincristine—lymphatic system cancer	0.00217	0.00224	CcSEcCtD
Pentazocine—Dysgeusia—Methotrexate—lymphatic system cancer	0.00213	0.0022	CcSEcCtD
Pentazocine—Nausea—Mitoxantrone—lymphatic system cancer	0.00211	0.00219	CcSEcCtD
Pentazocine—Vision blurred—Methotrexate—lymphatic system cancer	0.00205	0.00212	CcSEcCtD
Pentazocine—Vertigo—Methotrexate—lymphatic system cancer	0.00195	0.00202	CcSEcCtD
Pentazocine—Confusional state—Methotrexate—lymphatic system cancer	0.00179	0.00185	CcSEcCtD
Pentazocine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00177	0.00183	CcSEcCtD
Pentazocine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00171	0.00177	CcSEcCtD
Pentazocine—Anorexia—Methotrexate—lymphatic system cancer	0.00169	0.00175	CcSEcCtD
Pentazocine—Hypotension—Methotrexate—lymphatic system cancer	0.00166	0.00171	CcSEcCtD
Pentazocine—Insomnia—Methotrexate—lymphatic system cancer	0.0016	0.00166	CcSEcCtD
Pentazocine—Paraesthesia—Methotrexate—lymphatic system cancer	0.00159	0.00165	CcSEcCtD
Pentazocine—Dyspnoea—Methotrexate—lymphatic system cancer	0.00158	0.00163	CcSEcCtD
Pentazocine—Somnolence—Methotrexate—lymphatic system cancer	0.00158	0.00163	CcSEcCtD
Pentazocine—Decreased appetite—Methotrexate—lymphatic system cancer	0.00154	0.00159	CcSEcCtD
Pentazocine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00146	0.00151	CcSEcCtD
Pentazocine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00131	0.00135	CcSEcCtD
Pentazocine—Asthenia—Methotrexate—lymphatic system cancer	0.00127	0.00132	CcSEcCtD
Pentazocine—Pruritus—Methotrexate—lymphatic system cancer	0.00125	0.0013	CcSEcCtD
Pentazocine—Diarrhoea—Methotrexate—lymphatic system cancer	0.00121	0.00125	CcSEcCtD
Pentazocine—Dizziness—Methotrexate—lymphatic system cancer	0.00117	0.00121	CcSEcCtD
Pentazocine—Vomiting—Methotrexate—lymphatic system cancer	0.00113	0.00117	CcSEcCtD
Pentazocine—Dermatitis—Methotrexate—lymphatic system cancer	0.00112	0.00116	CcSEcCtD
Pentazocine—Headache—Methotrexate—lymphatic system cancer	0.00111	0.00115	CcSEcCtD
Pentazocine—Nausea—Methotrexate—lymphatic system cancer	0.00105	0.00109	CcSEcCtD
